Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Daily briefing: Woman cleared of HIV after transplant with umbilical-cord blood

Sign up for Nature Briefing

Hello Nature readers, would you like to get this Briefing in your inbox free every day? Sign up here.

Coloured scanning electron micrograph (SEM) of HIV particles (yellow) budding from the membrane of a host cell (blue).

HIV particles (yellow) bud from a host cell (blue).Thomas Deerinck, NCMIR/Science Photo Library

Cord blood clears woman of HIV

A woman in the United States has become the third person to be cured of HIV. She was treated with a new method: a transplant with umbilical-cord blood. The woman stopped antiretroviral therapy 37 months after the transplant and, more than 14 months later, still shows no signs of HIV in blood tests. Two other people have been cleared of HIV after a cancer-treating bone-marrow transplant. Transplanting cord blood, instead of bone marrow, allowed researchers to use a partially matched donor for the woman, who is mixed race, while giving her immune system a boost with blood from a close relative. This fresh approach could offer the promise of treatment to more HIV-positive people, regardless of their race or ethnicity.

The New York Times | 5 min read

Zero-COVID versus Omicron in Hong Kong

A surge in Omicron cases is overwhelming the health system in Hong Kong, where officials continue to pursue a zero-COVID strategy. Hong Kong has some of the world’s tightest COVID-19 restrictions. Officials have announced that they have secured thousands of apartments and hotel rooms to isolate new cases in an attempt to curtail the spread of Omicron. Some public-health researchers say that getting people to isolate at home could be a more sustainable policy.

Wall Street Journal | 4 min read

Glowing fish invade Brazil’s creeks

Zebrafish (Danio rerio) that have been genetically engineered to glow red and green have escaped fish farms in Brazil and invaded creeks in the Atlantic Forest, according to an ecological survey of the area. The neon fish, trademarked as Glofish, were the first transgenic species to be sold commercially in the 2000s, and became popular pets. They are now a rare example of transgenic animals accidentally escaping and thriving in nature. Researchers say the fish population could expand enough to threaten the local biodiversity, for example by competing with native species for the same food or preying on them. Others aren’t too worried, because the bright colour of the fish could make them a target for predators.

Science | 5 min read

Reference: Neotropical Fauna and Environment paper

Features & opinion

Policymakers: pandemics disable people

Decades after the polio vaccine almost wiped out the disease, a proportion of survivors relapsed with post-polio syndrome. Influenza epidemics have left a long tail of neurological disabilities. Looking at the history of pandemics, science historian Laura Spinney questions how COVID-19 might force society to grasp that the body can be altered for a long period — even permanently — by infectious disease and to make the necessary accommodations.

Nature | 10 min read

When your implant becomes obsolete

“I remember exactly where I was,” says Barbara Campbell of the moment her retinal implant, which gave her some vision after a genetic condition called retinitis pigmentosa made her completely blind in her 30s, stopped working. She was on the New York City subway, “and all of a sudden I heard a little ‘beep, beep, beep’ sound”. The device shut down without warning when the company that made it, Second Sight Medical Products, went under. More than 350 people who use the device face an uncertain future in which it's unclear whether their implant can be repaired or maintained.

IEEE Spectrum | 20 min read

News & views

How Epstein–Barr virus sparks MS

Researchers who study multiple sclerosis (MS) are split into two main camps: most see autoimmunity as the driving factor for the illness, but a minority invoke viral culprits. Last month, a study of a large group of people followed over many years found that infection with the Epstein-Barr virus increased the likelihood of developing MS by more than 32-fold. But this associative connection lacked a causal, disease-triggering link. Now, evidence might settle the debate through a compromise solution, writes neurobiologist Hartmut Wekerle. Antibodies that attack the Epstein–Barr virus also recognize GlialCAM, a protein that is in glial cells in the brain.

Nature | 9 min read

This News & Views article is exclusively available to readers with subscriber access to Nature. Click here for help getting logged in with your institution’s subscription.

Infographic of the week

From pee to products. 4 diagrams showing how urine can be recycled.

Separating urine from other sewage could reduce pollution, save water, produce better fertilizers and lessen the strain on sewer systems. But there are big obstacles to radically re-engineering one of the most basic aspects of life. (Nature | 13 min read)

See more of the week’s key infographics, selected by Nature’s news and art teams.


“Anyone who claims ‘basic’ biology is on their side probably shouldn’t be trusted anyways — in all my years in science, I have yet to encounter any indication that biology is in any way basic.”

Comparative geneticist Jess McLaughlin explores how to teach topics such as the genetics of sex determination, the developmental pathways associated with reproductive phenotypes and sex-linked inheritance in an inclusive way. (Personal blog | 12 min read)


This newsletter is always evolving — tell us what you think! Please send your feedback to

Flora Graham, senior editor, Nature Briefing

With contributions by Anne Marie Conlon and Anna Nowogrodzki

Nature Careers


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing


Quick links